Phase 1 Data Presented on First Oral Combination 17β-Estradiol and Progesterone Capsule to Treat Menopausal Symptoms Being Developed for FDA Review

Phase 3 REPLENISH Trial Now Under Way

Investigational hormone therapy also avoids use of peanut oil, a known allergen

TherapeuticsMD, Inc. (NYSE MKT: TXMD) - Pharmacokinetic study being presented tomorrow evening in a poster session at The North American Menopause Society 2013 Annual Meeting in Dallas suggests that the first combination 17β-estradiol and progesterone capsule in clinical development may have overcome the well-recognized difficulties of achieving good bioavailability with oral administration of these hormones in combination.

Agenus Inc. - "Agenus and GSK Work Together in the Fight Against Malaria"

Agenus Inc. (Nasdaq:AGEN) today published a new blog post on The Chairman's Blog, written by the company's Chairman and CEO, Dr. Garo Armen. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Agenus Chairman and CEO, Dr. Garo Armen, writes about GSK's newly announced Phase 3 data for their RTS,S malaria vaccine candidate containing Agenus' QS-21 Stimulon adjuvant. He reflects on the companies' collaboration in their fight against malaria and results from additional QS-21-containing programs he expects to see in the near future. Read the full blog post on TheChairmansBlog.com (http://www.thechairmansblog.com/garo-armen/2013-10/agenus-and-gsk-work-together-in-the-fight-against-malaria.html).

Arrowhead Completes Enrollment in Phase 1 Study of ARC-520 for the Treatment of Chronic Hepatitis B

- Safety and tolerability support advancement of ARC-520 into Phase 2a

Arrowhead Research Corporation (ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completed enrollment in a Phase 1 clinical trial of ARC-520, its RNAi-based candidate against chronic hepatitis B virus infection. Initial data indicate that ARC-520 is generally safe and well tolerated at all six dose levels studied, enabling the company to proceed with plans to initiate a Phase 2a pilot efficacy study in chronic HBV patients.

Tekmira Presents TKM-PLK1 Data at 6th Annual North American Neuroendocrine Tumor Society (NA-NETS) Conference

New Data Shows Positive Chromogranin-A Biomarker Results in GI-NET Patient

Phase I/II Clinical Trial with TKM-PLK1 Ongoing in Patients with Advanced Gastrointestinal Neuroendocrine Tumors (GI-NET) or Adrenocortical Carcinoma (ACC)

Tekmira Pharmaceuticals Corporation (TKMR) (TKM.TO), a leading developer of RNA interference (RNAi) therapeutics, today announced that it presented additional TKM-PLK1 data at the 6th Annual NET Conference hosted by the North American Neuroendocrine Tumor Society (NA-NETS) to be held in Charleston, South Carolina from October 4-5, 2013.